MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
DBV Technologies S.A. Operating Cycle 2011-2026 | DBVT
Annual Operating Cycle DBV Technologies S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 71.3 | - | - | - | - | - | 17.5 K | 10.6 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.5 K | 71.3 | 9.37 K |
Quarterly Operating Cycle DBV Technologies S.A.
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.6 | - | 48.9 | 56.4 | 21.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 56.4 | 21.6 | 40.4 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adagene
ADAG
|
53.8 | $ 1.65 | 7.91 % | $ 92.9 M |  China |
 |
AstraZeneca PLC
AZN
|
206 | $ 93.52 | -1.2 % | $ 96.9 B |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Biogen
BIIB
|
452 | $ 184.48 | -1.67 % | $ 26.9 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Catalyst Biosciences
CBIO
|
410 | $ 10.84 | 0.46 % | $ 714 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
364 | $ 37.35 | -0.4 % | $ 3.86 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
137 | $ 23.18 | 2.02 % | $ 2.75 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
40.8 | - | -0.23 % | $ 916 M | USA |
 |
Celldex Therapeutics
CLDX
|
86.5 | $ 25.59 | -6.54 % | $ 1.65 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Cellectis S.A.
CLLS
|
136 | $ 4.22 | -4.2 % | $ 116 M |  France |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
195 | $ 29.43 | 6.09 % | $ 1.43 B | USA |
 |
Acorda Therapeutics
ACOR
|
394 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 66.05 | 2.3 % | $ 8.83 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
2 K | $ 55.11 | 3.49 % | $ 4.45 B | USA |
 |
Abeona Therapeutics
ABEO
|
387 | $ 5.14 | -1.06 % | $ 110 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 55.17 | 2.47 % | $ 4.65 B |  Schweiz |
 |
Axon Enterprise
AXON
|
116 | $ 632.29 | 0.09 % | $ 47.9 B | USA |
 |
ADiTx Therapeutics
ADTX
|
841 | $ 0.81 | 1.96 % | $ 10.7 K | USA |
 |
Aytu BioScience
AYTU
|
360 | $ 2.7 | 2.27 % | $ 17 M | USA |